Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer

Published:2013 Issue:1 Volume:11 Page:215
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:Journal of Translational Medicine

Author:

Guo Zhiqiang,Cheng Dali,Xia Zhijun,Luan Meng,Wu Liangliang,Wang Gang,Zhang Shulan

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference36 articles.

1. Cancer statistics, 2013

2. Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis

3. Immunotherapy for Ovarian Cancer: What's Next?

4. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells

5. Phenotypic and Functional Analysis of Tumor-Infiltrating Lymphocytes Compared with Tumor-Associated Lymphocytes from Ascitic Fluid and Peripheral Blood Lymphocytes in Patients with Advanced Ovarian Cancer

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of TIM-3 in ovarian cancer: the forsaken cop or a new noble;Frontiers in Immunology;2024-08-13

2. Immune checkpoint inhibitors: breakthroughs in cancer treatment;Cancer Biology & Medicine;2024-05-24

3. Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review;Medical Oncology;2024-03-27

4. TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing Mice;Cancers;2024-03-14

5. Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party;Molecular Therapy: Oncology;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3